| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dreyer Scott | EVP & Chief Commercial Officer | C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON | /s/ Colleen Tupper as Attorney-In-Fact For Scott Dreyer | 12 Feb 2026 | 0001746251 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | COLL | Common Stock | Award | $0 | +19,023 | +18% | $0.000000 | 122,636 | 10 Feb 2026 | Direct | F1 |
| transaction | COLL | Common Stock | Award | $0 | +30,702 | +25% | $0.000000 | 153,338 | 10 Feb 2026 | Direct | F2 |
| transaction | COLL | Common Stock | Tax liability | $466,425 | -9,977 | -6.5% | $46.75 | 143,361 | 10 Feb 2026 | Direct | F3 |
| transaction | COLL | Common Stock | Tax liability | $1,010,501 | -21,615 | -15% | $46.75 | 121,746 | 10 Feb 2026 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. |
| F2 | Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 30,702 performance share units ("PSUs") granted in the Issuer's three prior fiscal years. |
| F3 | Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs. |
| F4 | Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs. |